- STOP-HZ study aims to determine the optimal timing for herpes zoster vaccination in rheumatoid arthritis patients starting JAK inhibitor therapy.
- The primary endpoint will measure VZV-specific IgG antibody titers at week 12 compared to baseline.
- Eligible participants must be 50 or older with moderate to high disease activity despite antirheumatic therapy.
- Enzyme immunoassay and ELISPOT assays will be employed to measure immune responses.
- Safety monitoring includes tracking herpes zoster events, disease activity exacerbation, and adverse events.
JAK Inhibitors & RZV Vaccination Timing: Study Underway
Conexiant
January 13, 2025
